QLQi Liu

Qi Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qi Liu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Mingyong Han

    Cancer Therapy and Research Center, Shandong Provincial Hospital, Shandong University, Jinan 250021, PR China

    4 shared publications
  • Jiekai Yu

    Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China

    2 shared publications
  • Jihui Jia

    Department of Microbiology/Key Laboratory for Experimental Teratology of Chinese Ministry of Education, School of Medicine, Shandong University, Jinan 250012, P.R China

    2 shared publications
  • Man Jiang

    Cancer Therapy and Research Center, Shandong Provincial Hospital, Shandong University, Jinan 250021, P.R. China

    2 shared publications
  • Shu Zheng

    Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China

    2 shared publications
  • Xiaoya Xu

    Cancer Therapy and Research Center, Shandong Provincial Hospital, Shandong University, Jinan 250021, P.R. China

    2 shared publications

Latest Publications

  • Open Access

    Identification of Osteoarthritis Biomarkers by Proteomic Analysis of Synovial Fluid

    by My Han, Jj Dai, Y Zhang, Q Lin, M Jiang, Xy Xu, Q Liu

    Objective: To use proteomic analysis to identify novel candidate biomarker proteins in synovial fluid for the differential diagnosis of osteoarthritis and rheumatoid arthritis. Methods: Synovial fluid samples were analysed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Data were used to generate an artificial neural network (ANN). The identification of one protein peak was confirmed via Western blotting. Results: Fluid samples were analysed from 36 patients with osteoarthritis and 24 with rheumatoid arthritis. In total, three protein peaks (mass-to-charge ratio [m/z] 3893, 10576 and 14175 Da) were identified as potential biomarkers for osteoarthritis. The ANN differentiated between osteoarthritis and rheumatoid arthritis with a sensitivity of 89.4% and a specificity of 91.2%. The protein peak at m/z 10 576 was identified as S100 calcium binding protein A12 (S100A12). Conclusions: A combination of SELDI-TOF-MS and ANN identified osteoarthritis biomarkers. SELDI-TOF-MS may be a useful tool in the screening of synovial fluid for osteoarthritis diagnosis.


  • Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer

    by Mingyong Han, Jianjian Dai, Ying Zhang, Qi Lin, Man Jiang, Xiaoya Xu, Qi Liu, Jihui Jia

    The aim of this study was to identify serum protein fingerprints of small cell lung cancer (SCLC) and potential biomarkers related to chemotherapy resistance of SCLC with surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS). A total of 60 SCLC patients and 48 age- and sex-matched healthy individuals were enrolled. The chemotherapy regimen was cisplatin plus etoposide. All patients received two cycles of chemotherapy. Serum protein profiles were detected using SELDI-TOF MS and the spectra were analyzed with support vector machines (SVMs). Western blotting was performed to verify the results of SELDI-TOF MS. Three top scored peaks, at m/z of 6269, 9043 and 13124 Da, were finally selected as potential biomarkers for detection of SCLC. The SVM classifier separated the SCLC from the healthy samples in the blind test, with a sensitivity of 92.4% and a specificity of 92.5%. For the 56 eligible chemotherapy patients, 4 had a complete response (7.14%), 39 patients had a partial response (69.6%), 9 patients had a stable disease (16.1%) and 4 patients had a progressive disease (7.14%). The model constructed using two protein peaks with m/z of 8830 and 10468 Da separated the chemotherapy-resistant group from the chemotherapy-sensitive group with a sensitivity of 80.0% and a specificity of 80.0%. Initial protein database searching identified 10468 Da as S100-A9 which was confirmed by western blotting. The present results suggest that the combination of SELDI-TOF MS with SVM may provide a useful means in the search for serum biomarkers for predicting chemotherapy resistance in patients with SCLC.


  • Primary tumor regulates the pulmonary microenvironment in melanoma carcinoma model and facilitates lung metastasis

    by Mingyong Han, Jiying Xu, Yuli Bi, Man Jiang, Xiaoya Xu, Qi Liu, Jihui Jia

    Lung is a common site for the occurrence of melanoma metastasis, the mechanism by which primary melanoma affects the lungs before tumor cells arrival is poorly understood. The aim of this study was to explore lung microenvironment response to primary melanoma in the premetastatic phase. Melanoma cells (B16) were implanted into the Balb/c mice back, pulmonary inflammation response was analyzed by wet/dry ratios and H&E staining, the relationship between inflammation cells and metastatic foci was analyzed by bone marrow transplant mouse model, pulmonary vasculature was further analyzed by whole mount staining, and the circulating levels of proinflammatory cytokines in sera were evaluated by mouse cytokine array. In the premetastatic stage, significant inflammation response in lungs was induced by a distant primary melanoma, inflammation cells colonize in premetastatic sites before tumor cells arrived, and the sites of inflammation cells clusters are tumor metastasis sites. VEGF, M-CSF and TNF-α may be the underlying factors responsible for the increased metastasis in the B16-bearing mice. Treatment with celecoxib had effects on inflammation response and reduced cancer metastasis. In the premetastatic phase, the melanoma induces pulmonary inflammation response, changes the lung environment and then facilitates lung metastasis. Thus, inhibition of lung inflammation may provide potential targets for the prevention of metastasis.


  • Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer

    by Mingyong Han, Qi Liu, Jiekai Yu, Shu Zheng

    Background: Empirical chemotherapy for patients with non-small cell lung cancer (NSCLC) is recommended, even without knowledge of the tumor's specific biological characteristics, and many patients may not benefit. The goal of this study was to identify potential serum biomarkers that influence resistance to chemotherapy, and to build a model that could be used to predict resistance to chemotherapy of patients with advanced NSCLC. Methods: A total of 97 NSCLC patients were classified as stage IIIB and stage IV. The chemotherapy regimen was cisplatin plus docetaxel. All patients received two cycles of chemotherapy. Serum protein profiles were detected using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) and the spectra were analyzed with a support vector machine (SVM). Results: For the 93 eligible patients, 22 patients had a partial response (23.7%); 27 patients had stable disease (29.0%) and 44 (47.3%) had progressive disease. One hundred and twenty-eight mass peaks were detected from the chemotherapy sensitive group and the chemotherapy resistant group by receiver operator characteristic curve. The top 10 peaks with the highest area under the curve values were selected, randomly combined, and fed into the SVM. The SVM model with the highest accuracy was used as the diagnostic model. The model constructed using five protein peaks with mass/charge ratios of 3955 Da, 6207 Da, 7992 Da, 9214 Da, and 15,086 Da separated the chemotherapy resistant group from the chemotherapy sensitive group with a sensitivity of 83.3% and specificity of 85.7%. Conclusions: SELDI-TOF MS may provide a useful means in the search for serum biomarkers for predicting chemotherapy resistance in patients with advanced NSCLC. Clin Chem Lab Med 2010;48:863–7.


  • Detection and significance of serum protein markers of small‐cell lung cancer

    by Mingyong Han, Qi Liu, Jiekai Yu, Shu Zheng

    Currently, no satisfactory biomarkers are available to screen for small-cell lung cancer (SCLC). We applied a surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) ProteinChip system to detect 150 serum samples (including 54 SCLC patients, 24 non-small cell lung cancer [NSCLC] patients, 32 pneumonia patients, and 40 healthy individuals). The spectra data were analyzed by support vector machine (SVM) and potential biomarkers were chosen for the system training and used to construct diagnostic model. Pattern 1, constructed of four protein peaks with mass/charge (m/z) of 4,293 Da, 4,612 Da, 6,455 Da, and 7,582 Da, separated SCLC patients from the healthy individuals with a sensitivity of 88.9% and a specificity of 85.7%. This pattern performed significantly better than the current marker, neuron-specific enolase (NSE) (P<0.05). Pattern 2, constructed of protein peaks with mass/charge (m/z) of 2,764 Da and 1,7368 Da, separated SCLC from pneumonia with a sensitivity of 88.9% and a specificity of 91.7%. Pattern 3, constructed of another three protein peaks with m/z of 3,912 Da, 7,562 Da, and 13,777 Da, separated SCLC from NSCLC. The sensitivity and specificity were 83.3% and 75.0%, respectively. These results suggested that SELDI-TOF MS combined with support vector machine yields significantly higher sensitivity and specificity for the detection of serum protein of SCLC. J. Clin. Lab. Anal. 22:131–137, 2008.